Peer-reviewed article

Serotonin 5-HT<sub>2B</sub> receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents.

Expert opinion on drug safetyJul 1, 2023Canada15 citationsDOI: 10.1080/14740338.2023.2248883

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinMDMALSD

Keywords

Valvular Heart DiseaseEcstasyFda GuidanceLysergic Acid Diethylamide (Lsd)5Ht2b Receptor Agonism

View paper

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticlePsilocybin

Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress.

Viña SM

Europe PMC2025

ArticlePsilocybin

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.

Portes MAM, Bertoglio LJ

Europe PMC2026

ArticlePsilocybin

In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials.

Soliman PS, Curley DE, Capone C +2

Europe PMC2024